|Bid||24.68 x 3000|
|Ask||24.71 x 1200|
|Day's range||23.87 - 24.77|
|52-week range||13.67 - 27.80|
|Beta (5Y monthly)||1.53|
|PE ratio (TTM)||26.57|
|Earnings date||29 Jul 2020 - 03 Aug 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||26.69|
Exelixis, Inc. (NASDAQ: EXEL) today announced phase 1b clinical trial results for the combination of cabozantinib (CABOMETYX®) and atezolizumab (TECENTRIQ®) in patients with locally advanced or metastatic solid tumors. The data from three expansion cohorts of the COSMIC-021 trial will be presented during the 2020 American Society of Clinical Oncology Virtual Scientific Program (ASCO20). Results from the non-small cell lung cancer (NSCLC) and the metastatic castration-resistant prostate cancer (CRPC) cohorts will be presented as posters, and results from the urothelial carcinoma (UC) cohort will be presented as a poster discussion; all three presentations will be available on demand for ASCO20 registrants beginning Friday, May 29 at 8:00 a.m. ET.
Exelixis (NASDAQ: EXEL) and bluebird bio (NASDAQ: BLUE) are two biotech companies that have been moving in opposite directions on the stock market this year. While Exelixis has provided healthy gains -- its stock is up by 52.1% year to date -- Bluebird's shares have slid by 35.2% since the beginning of the year. With this backdrop in mind, it might be tempting to pick Exelixis as the better stock to buy.
Exelixis, Inc. (Nasdaq: EXEL) today announced that members of Exelixis’ management team will participate in fireside chats at the following virtual investor conferences in May:
Exelixis (EXEL) delivered earnings and revenue surprises of 15.38% and 6.79%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2020 and provided an update on progress toward fulfilling its key corporate objectives, as well as commercial and clinical development milestones.
Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exelixis, Inc. (Nasdaq: EXEL) announced today that its first quarter 2020 financial results will be released on Tuesday, May 5, 2020 after the markets close. At 5:00 p.m. EDT / 2:00 p.m. PDT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company’s website.
BMS and Exelixis Announce Positive Topline Results from Pivotal Phase 3 CheckMate -9ER Trial Evaluating Opdivo in Combination with CABOMETYX...
Exelixis, Inc. (Nasdaq: EXEL) today announced that members of Exelixis’ management team will participate in a fireside chat as part of the 19th Annual Needham Healthcare Conference on Wednesday, April 15, 2020 at 11:20 AM EDT / 8:20 AM PDT. Due to the ongoing COVID-19 pandemic, the conference has been converted to a virtual event.
Exelixis, Inc. (NASDAQ: EXEL) today announced that Takeda Pharmaceutical Company Limited (Takeda), its partner responsible for the clinical development and commercialization of CABOMETYX® (cabozantinib) in Japan, received approval from the Japanese Ministry of Health, Labor and Welfare to manufacture and market CABOMETYX as a treatment for patients with curatively unresectable or metastatic renal cell carcinoma (RCC).
Exelixis, Inc. (Nasdaq: EXEL) today announced that George A. Scangos, Ph.D. has notified the company of his decision to retire from the Exelixis Board of Directors. Dr. Scangos will not stand for re-election to the Board at the company’s 2020 Annual Meeting of Stockholders, which has been tentatively scheduled for May 20, 2020; his resignation from the Board will take effect that same day.
Exelixis (EXEL) delivered earnings and revenue surprises of 46.67% and -0.15%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Roche (RHHBY) submits sBLA for the label expansion of the Tecentriq-Avastin combo to treat HCC patients who have not received prior systemic therapy.